Nothing Special   »   [go: up one dir, main page]

CO6761388A2 - Composiciones pharmaceuticas que comprenden alisporivir - Google Patents

Composiciones pharmaceuticas que comprenden alisporivir

Info

Publication number
CO6761388A2
CO6761388A2 CO13142692A CO13142692A CO6761388A2 CO 6761388 A2 CO6761388 A2 CO 6761388A2 CO 13142692 A CO13142692 A CO 13142692A CO 13142692 A CO13142692 A CO 13142692A CO 6761388 A2 CO6761388 A2 CO 6761388A2
Authority
CO
Colombia
Prior art keywords
alisporivir
pharmaceutical compositions
based pharmaceutical
provides lipid
compositions
Prior art date
Application number
CO13142692A
Other languages
English (en)
Inventor
Elisabete Goncalves
Karin Rapp
Bertrand Sutter
Frank Stowasser
Bjoern Trupp
Sebastian Chabaut
Julien Thorens
Original Assignee
Novartis Ag
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6761388(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Debiopharm Sa filed Critical Novartis Ag
Publication of CO6761388A2 publication Critical patent/CO6761388A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona composiciones farmacéuticas basadas en lípido, las cuales comprenden alisporivir.
CO13142692A 2010-12-13 2013-06-14 Composiciones pharmaceuticas que comprenden alisporivir CO6761388A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42249910P 2010-12-13 2010-12-13
IB2011000319 2011-02-18
IB2011000653 2011-03-25

Publications (1)

Publication Number Publication Date
CO6761388A2 true CO6761388A2 (es) 2013-09-30

Family

ID=45346477

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13142692A CO6761388A2 (es) 2010-12-13 2013-06-14 Composiciones pharmaceuticas que comprenden alisporivir

Country Status (33)

Country Link
US (2) US20140005123A1 (es)
EP (1) EP2651396B1 (es)
JP (2) JP6259288B2 (es)
KR (1) KR101928589B1 (es)
CN (2) CN103282022A (es)
AR (1) AR084235A1 (es)
AU (3) AU2011344331A1 (es)
BR (1) BR112013014606A2 (es)
CA (1) CA2819167C (es)
CL (1) CL2013001684A1 (es)
CO (1) CO6761388A2 (es)
CY (1) CY1119468T1 (es)
DK (1) DK2651396T3 (es)
EC (1) ECSP13012679A (es)
ES (1) ES2643135T3 (es)
HR (1) HRP20171485T1 (es)
HU (1) HUE036784T2 (es)
IL (1) IL226554A (es)
JO (1) JO3337B1 (es)
LT (1) LT2651396T (es)
MA (1) MA34709B1 (es)
MX (1) MX351667B (es)
MY (1) MY165088A (es)
NZ (1) NZ610950A (es)
PE (1) PE20140104A1 (es)
PL (1) PL2651396T3 (es)
PT (1) PT2651396T (es)
RU (1) RU2639482C2 (es)
SG (2) SG10201509833YA (es)
SI (1) SI2651396T1 (es)
TW (1) TWI599368B (es)
WO (1) WO2012080176A2 (es)
ZA (1) ZA201303721B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
TWI527813B (zh) 2010-12-13 2016-04-01 亞雷生物製藥股份有限公司 作為III型受體酪胺酸激酶抑制劑之經取代N-(1H-吲唑-4-基)咪唑并 [1,2-a]吡啶-3-甲醯胺化合物
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
FR2697040B1 (fr) 1992-10-21 1994-12-30 Ind Entreprise Elément de protection contre le bruit et son utilisation.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
WO1999056727A2 (en) * 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
WO2000001715A1 (fr) * 1998-07-01 2000-01-13 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
UA88484C2 (ru) * 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Hcv 치료용 조성물
GB0504950D0 (en) 2005-03-10 2005-04-20 Novartis Ag Organic compositions
AU2009312535B2 (en) 2008-11-06 2015-03-26 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير

Also Published As

Publication number Publication date
EP2651396A2 (en) 2013-10-23
AR084235A1 (es) 2013-05-02
TW201306859A (zh) 2013-02-16
KR20140018858A (ko) 2014-02-13
HRP20171485T1 (hr) 2017-11-17
CN103282022A (zh) 2013-09-04
AU2017245296A1 (en) 2017-11-02
CA2819167C (en) 2019-12-31
MX2013006525A (es) 2013-08-01
PL2651396T3 (pl) 2017-12-29
US20140005123A1 (en) 2014-01-02
AU2011344331A1 (en) 2013-07-11
CA2819167A1 (en) 2012-06-21
RU2639482C2 (ru) 2017-12-21
JP6259288B2 (ja) 2018-01-10
JO3337B1 (ar) 2019-03-13
ECSP13012679A (es) 2013-08-30
JP2018027949A (ja) 2018-02-22
DK2651396T3 (en) 2017-10-23
KR101928589B1 (ko) 2018-12-12
SG190894A1 (en) 2013-07-31
IL226554A (en) 2017-12-31
JP2014503520A (ja) 2014-02-13
ES2643135T3 (es) 2017-11-21
EP2651396B1 (en) 2017-07-12
NZ610950A (en) 2015-07-31
CN105125489A (zh) 2015-12-09
LT2651396T (lt) 2017-09-25
AU2016201053B2 (en) 2017-07-13
RU2013132543A (ru) 2015-01-20
AU2016201053A1 (en) 2016-03-10
HUE036784T2 (hu) 2018-08-28
MA34709B1 (fr) 2013-12-03
WO2012080176A2 (en) 2012-06-21
MX351667B (es) 2017-10-24
TWI599368B (zh) 2017-09-21
US10188696B2 (en) 2019-01-29
SI2651396T1 (sl) 2017-11-30
CL2013001684A1 (es) 2014-01-10
PT2651396T (pt) 2017-10-18
BR112013014606A2 (pt) 2017-06-06
MY165088A (en) 2018-02-28
CN105125489B (zh) 2019-04-16
WO2012080176A3 (en) 2012-08-09
US20160367624A1 (en) 2016-12-22
CY1119468T1 (el) 2018-03-07
SG10201509833YA (en) 2016-01-28
PE20140104A1 (es) 2014-02-04
ZA201303721B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34817A (es) Tienopirimidinas
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34765A (es) Compuestos novedosos.
MX2013002264A (es) Composiciones pesticidas.
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
UY34654A (es) Inhibidores de la beta-secretasa
JO3755B1 (ar) تركيبات تستوستيرون
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CY1119468T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη
UY34677A (es) Imidazopiridazinas sustituidas
BR112014028443A2 (pt) composição estéril.
CL2009001973S1 (es) Mostrador.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
TR201007106A1 (tr) Sefpodoksim proksetil formülasyonları.
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
TR200903176A1 (tr) Çoklu blister.
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013016029A2 (pt) composição farmacêutica de fosfomicina.
IT1406067B1 (it) Composizioni eudermiche.
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
TN2010000567A1 (fr) المحطة الكهرمائية الشمسية
TN2010000017A1 (fr) مستحضر تجميلي دوائي